TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05860803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LungTrainers
Description: A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LungTrainers Pulmonary Rehabilitation regime
Description: Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.
Study: NCT06128395

Intervention type: OTHER
Intervention: Frozen embryo transfer
Description: A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy

Intervention type: OTHER
Intervention: Frozen embryo transfer
Description: A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
Study: NCT06463327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCB008
Description: TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
Study: NCT01325389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-Mel

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06364540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Nebulized ketamine administered at 0.75 mg/kg via BAN

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Nebulized fentanyl administered at 3 mcg/kg via BAN
Study: NCT04772755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy® and Electronic Game
Description: Buzzy® was applied according to manufacturers directions and an electronic game was played. The participant was observed for 20 minutes post vaccination.
Study: NCT05768880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC-CAR4BRAIN
Description: Courses of weekly intraventricular CNS administered SC-CAR4BRAIN infusions for 3 weeks, then 1 week off

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC-CAR4BRAIN
Description: Courses of weekly intraventricular CNS administered SC-CAR4BRAIN infusions for 3 weeks, then 1 week off
Study: NCT05151484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Participants will receive 20 μg teriparatide per day via subcutaneous injections. Participants, and if needed a caregiver, will be trained in the subcutaneous administration of teriparatide according to the manufacturer's guidelines. The investigators will measure serum calcium, BSAP and TRAP-5b levels via blood draws at quarterly monitoring visits. If BSAP or TRAP-5b do not increase compared to baseline or decrease after any quarter, participants will be contacted and correct administration will be reviewed. Serum calcium is measured for safety to avoid hypo- and hypercalcemia. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
Study: NCT05151146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANJ900
Description: Metformin hydrochloride delayed-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANJ900
Description: Metformin hydrochloride delayed-release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin IR
Description: metformin hydrochloride
Study: NCT05890794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ilofotase Alfa, 0.8 mg/kg
Description: Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ilofotase Alfa, 3.2 mg/kg
Description: Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
Study: NCT04911907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
Study: NCT05331209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Weekly acupuncture treatments, for 8 weeks (8 treatments)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Weekly acupuncture treatments, for 8 weeks (8 treatments)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture-Acupressure
Description: Weekly acupuncture, for 8 weeks, with daily self-acupressure by the patient at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture-Acupressure
Description: Weekly acupuncture, for 8 weeks, with daily self-acupressure by the patient at home.
Study: NCT06115382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Cueing Training
Description: Group classes led by a music therapist and using singing as a self-generated cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Cueing Training
Description: Group classes led by a music therapist and using music as an external cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
Study: NCT04941807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet-poor plasma
Description: Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
Study: NCT03843385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encapsulated faecal microbiota filtrate
Description: Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: encapsulated faecal microbiota
Description: Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sterile saline encapsulated in hypromellose capsules and frozen.
Study: NCT05921695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline infusion and Ringer lactate infusion
Description: The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline infusion and Ringer lactate infusion
Description: The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
Study: NCT06283797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OmniPod 5
Description: Participants will be trained to use OmniPod 5 to treat type 1 diabetes for 1 year
Study: NCT03713970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: celtra duo press
Description: celtra duo press ingot

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: celtra duo press
Description: celtra duo press ingot

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPS e.max press
Description: IPS e.max press ingot

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max press
Description: IPS e.max press ingot
Study: NCT06244082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOC 1044
Description: AOC 1044 will be administered via intravenous (IV) infusion
Study: NCT05917990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Text-Messaging Micro-Intervention
Description: Participants receive text-messages consisting of information and skills relevant to improving couples' communication and relationship functioning.
Study: NCT06373926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood withdrawal
Description: blood withdrawal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood withdrawal
Description: blood withdrawal
Study: NCT05311943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olverembatinib
Description: olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
Study: NCT05205538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint interval exercise training
Description: A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint interval exercise training
Description: A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.
Study: NCT05969756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: Thirty-eight permanent molars will receive 5% sodium fluoride varnish application every three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional etch and rinse sealant
Description: Thirty-eight permanent molars will receive conventional etch and rinse sealant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self-etch sealant
Description: Thirty-eight permanent molars will receive self-etch sealant
Study: NCT05125718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.85% synthetic antimicrobial peptide TAPS-18
Description: commercially available synthetic antimicrobial peptide gel for periodontal disease treatment

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.9% normal saline
Description: commercially available normal saline Sodium Chloride irrigation solution
Study: NCT05557539

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples, urine samples and nasopharyngeal swabs
Description: The following samples will be collected: First time point : 6 blood sample tubes (5mL EDTA, 5mL heparinized and 7.5mL heparinized, 5mL citrate, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium). Second time point : 5 blood sample tubes (5mL EDTA,5mL heparinized and 7.5mL heparinized, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium).
Study: NCT04950192

Intervention type: DEVICE
Intervention: ICE Image guidance
Description: ICE image guidance will be used on all patients undergoing planned cardiac catheterization procedures
Study: NCT05099055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.004 MG/ML [Precedex]
Description: Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
Study: NCT05484531

Intervention type: DEVICE
Intervention: CLEAR
Description: Reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude
Study: NCT06109051

Intervention type: DEVICE
Intervention: EndeavorOTC
Description: EndeavorOTC™ is an over-the-counter digital therapeutic designed to improve attention function, ADHD symptoms, and quality of life in users 18 years of age and older with primarily inattentive or combined-type ADHD, who have been identified as having a significant attentional impairment. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is not intended to be a replacement for any form of ongoing treatment. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
Study: NCT06300125

Intervention type: PROCEDURE
Intervention: Cryoablation
Description: Percutaneous Cryoablation of Breast Cancer
Study: NCT06283797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: Participants will use Dexcom G6 for continuous glucose monitoring
Study: NCT06662630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency Oscillatory Ventilation
Description: Administer 10 minutes of high-frequency oscillatory ventilation in mechanically ventilated patients.
Study: NCT06078696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Premedication with diphenhydramine 50 mg PO is to be given 1 hour prior to siplizumab infusion. Premedication with hydrocortisone succinate 100 mg IV infused over 30 minutes and acetaminophen 650 mg PO are to be given at least 30 minutes prior to siplizumab infusion. Siplizumab 4.8 mg/kg total is given on Day -14 and 0.6mg/kg is given on days -6, -1, 0, and +1. It will be given as an IV infusion over 1 hour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exchange Transfusion
Description: Patient will undergo a red blood cell exchange transfusion to achieve a Hemoglobin S (HgbS) level \< 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Radiation dose is 2Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
Study: NCT05799729

Intervention type: DRUG
Intervention: Ketamine
Description: CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.

Intervention type: DRUG
Intervention: Ketamine
Description: CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.
Study: NCT05213104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: Flecainide 150 mg 6 months in addition to standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: Flecainide 150 mg 3 months in addition to standard of care
Study: NCT05223907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Etomidate will be used for general anesthesia
Study: NCT05891262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986196
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin
Description: Specified dose on specified days
Study: NCT05223907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be used for general anesthesia
Study: NCT04085068

Intervention type: OTHER
Intervention: cranioscaral treatment
Description: dural release
Study: NCT06078696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Standard institutional procedures should be followed for the processing and administration of stem cell products for infusion. The infused graft under no circumstances is to be irradiated. No in-line leukocyte filter should be used and no medications or fluids should be given piggyback through the catheter lumen used for infusion of stem cells. Vital signs should be monitored before beginning the infusion and periodically during administration and in accordance with institutional guidelines. Pre-medications prior to the graft infusion will be according to the institutions standard practice. Benadryl, epinephrine, hydrocortisone, and oxygen be available at the bedside, as well as an emergency medical code cart available in the vicinity of the patient, for emergency use in case of an infusion reaction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: Cyclophosphamide will be given on days +3 and +4 at a dose of 50 mg/kg. Hydration prior to cyclophosphamide should be given according to standard institutional practice. Day +3 dose should occur between 60 and 72 hours after graft infusion and day +4 post-transplant should occur approximately 24 hours after prior dose. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume or as per institutional standard practice. Cyclophosphamide will be dosed according to adjusted ideal body weight (AIBW) in patients weighing \> 125% ideal body weight (IBW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is to be given starting 1 hour prior to cyclophosphamide at the same dose (50 mg/kg) as a continuous infusion over 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Oral Tablet
Description: Sirolimus will be given orally with a loading dose of 12 mg, then followed by 4 mg orally daily. Dosage will be adjusted to a therapeutic target of 10 - 15ng/ml in first 3 months post transplant and 3-10 after 3 months. Sirolimus should be started on day +5. It will be continued until at least day 180. Sirolimus can be tapered or continued according to the treating physician discretion and the presence of absence of GVHD and/or degree of donor chimerism. Sirolimus should be continued if donor chimerism is less than 50% to prevent graft loss.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab or Biosimilar
Description: Rituximab (375 mg/m2/dose) will be administered on Days -14 and -6. In those subjects receiving ongoing renal replacement therapy, rituximab should be administered several hours after hemodialysis. The first rituximab solution for infusion should be administered intravenously at an initial rate of 50 milligrams/hour (mg/hr). The rate may be escalated by 50mg/hr every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions may be started at 100 milligrams/hour (mg/hr) and titrated by 100 mg/hr every 30 minutes to a maximum of 400mg/hr if the subject tolerated the first infusion.
Study: NCT06669351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: Day1: Take two tablets of ZX-7101A orally once (specification: 10mg/ tablet) with appropriate amount of warm water
Study: NCT06681350

Intervention type: DEVICE
Group type: OTHER
Intervention: Ocular surface imaging
Description: Telemedical examination of high-resolution, all-in-focus images of the cornea, sclera, conjunctiva, and lid margins for montioring of postoperative complications
Study: NCT06682728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan (SG)
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV